California is currently home to 5590 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis
Recruiting
This study evaluates either KRT-232 or TL-895 in treatment naïve patients with myelofibrosis (MF) The study will be conducted in 2 stages. Stage 1 will evaluate safety, tolerability, and efficacy of either KRT-232 (Arm 1) or TL-895 (Arm 2) in treatment naïve patients. Stage 2 will expand enrollment in Arm 1 and/or Arm 2 if expansion criteria is met.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2022
Locations: Innovative Clinical Research Institute, Glendale, California
Conditions: Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV-MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF)
The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections
Recruiting
The study is designed as an international, multicenter prospective cohort study. Patients with presumed glioblastoma (GBM) in- or near eloquent areas on diagnostic MRI will be selected by neurosurgeons. Patients will be treated following one of three study arms: 1) a craniotomy where the resection boundaries for motor or language functions will be identified by the "awake" mapping technique (awake craniotomy, AC); 2) a craniotomy where the resection boundaries for motor functions will be identif... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
05/05/2022
Locations: University of California, San Francisco, San Francisco, California
Conditions: Glioblastoma
KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF
Recruiting
This study evaluates KRT-232 in Combination With TL-895 for the Treatment of Relapsed or Refractory Myelofibrosis and KRT-232 for the Treatment of JAK Inhibitor Intolerant Myelofibrosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2022
Locations: The Oncology Institute of Hope, Whittier, California
Conditions: Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis
International REgistry of COnservative or Radical Treatment of Localized Kidney Tumors
Recruiting
Partial nephrectomy (PN) is the standard treatment for localized renal masses and should be preferred in clinical T1 (\<7 cm tumor diameter) renal tumors over radical nephrectomy (RN) whenever technically feasible. Nonetheless, indications, approaches, techniques for PN, and correct reporting of outcomes, are still a matter of great debate within the urology community. Concurrently, case-report series suggested that alternative strategies for the treatment of localized renal tumors (ablation tec... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2022
Locations: Institute of Urology, University of Southern California., Los Angeles, California
Conditions: Kidney Cancer
Multi-Atlas and Whole Body Radiomics Approaches for Image-Guided Treatment of Gynecologic Cancers
Recruiting
To compare acute toxicity and chemotherapy delivery for atlas-based IG-IMRT vs. PET/CT-based IG-IMRT vs. conventional RT, and assess the impact of treatment on changes in hematopoietic compensatory response. To develop and validate machine learning and radiomics techniques for dose accumulation, automated treatment planning, and prediction of treatment response.
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/27/2022
Locations: University of California, San Diego, La Jolla, California
Conditions: Gynecologic Cancer
Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions
Recruiting
This multi-arm, multi-site study investigates the safety, tolerability, and efficacy of stem cell therapy for the treatment of various acute and chronic conditions. Clinically observed initial findings and an extensive body of research indicate regenerative treatments are both safe and effective for the treatment of multiple conditions.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/27/2022
Locations: Southern California Hospital at Culver City / Southern California Hospital at Hollywood / Multiple US-based Sub-Investigator Sites, Culver City, California
Conditions: Autoimmune Diseases, Cardiovascular Disorders, Diabetes Complications, Integumentary Disease, Musculoskeletal Disorders, Neurodegenerative Disorders, Neurologic Disorders, Pulmonary Disorders, Sexual Dysfunction, Urologic Disorders, Viral Illness
Clinical and Genetic Analysis of ROP
Recruiting
Retinopathy of Prematurity (ROP) is a vascular disease affecting the retinas (back of the eye) of low birth weight infants. Although it can be treated effectively if diagnosed early, it continues to be a leading cause of childhood blindness in the United States and throughout the world. The investigators feel that this study will result in specific knowledge discovery about ROP, as well as general knowledge about how image-based data and genetic data can be combined to better understand clinical... Read More
Gender:
ALL
Ages:
1 year and below
Trial Updated:
04/18/2022
Locations: Stanford University, Palo Alto, California
Conditions: Retinopathy of Prematurity
Introducing Palliative Care (PC) Within the Treatment of End Stage Liver Disease (ESLD)
Recruiting
This is a comparative effectiveness study of two pragmatic models aiming to introduce palliative care for end stage liver disease patients. The 2 comparators are: Model 1: Consultative Palliative Care (i.e. direct access to Palliative Care provider), Model 2: Trained Hepatologist- led PC intervention (i.e. a hepatologist will receive formal training to deliver Palliative Care services) Primary Outcome: The change in quality of life from baseline to 3 months post enrollment as assessed by FACT-... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
04/05/2022
Locations: UCSF Fresno, Fresno, California
Conditions: End Stage Liver Disease
MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)
Recruiting
Study description - Patients will be randomized according to post-operative recurrence risk to either a high ligation of ileocolic artery or mesenteric sparing ileocolic resection for terminal ileal Crohn's disease. The primary endpoint 6-month endoscopic recurrence. Endpoints - Primary endpoint; 6 months Secondary endpoints at 1 and 5 years post ileocecal resection Study population - Adult Crohn's disease patients with medically refractory terminal ileal Crohn's disease undergoing a primary i... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/01/2022
Locations: Cedars-Sinai Hospital System, Los Angeles, California
Conditions: Crohn Disease
Non Exudative AMD Imaged With SS-OCT- Extension
Recruiting
The investigators wish to better understand the role of the choriocapillaris (CC) in the formation and progression of non-exudative in age related macular degeneration (armd) by imaging the retinal pigment epithelium (rpe) and the choroidal microvasculature and by studying their inter-dependence to determine if the loss of the CC could prove useful as an anatomic clinical trial endpoint in future drug trials.
Gender:
ALL
Ages:
All
Trial Updated:
03/08/2022
Locations: University of California Los Angeles Doheny Eye Institute, Los Angeles, California
Conditions: Dry Macular Degeneration
Bone Marrow Aspirate Concentrate (BMAC)Treatment for Knee Osteoarthritis
Recruiting
The purpose of this study is to investigate the safety and effectiveness of bone marrow aspirate concentrate (BMAC) in patients with moderate to severe osteoarthritis of the knee. BMAC provides a rich source of mesenchymal stem cells (MSCs) and is a stem cell-based therapy that has been reported to preserve or improve the structure of joints. The Angel System is the device used in this study to concentrate bone marrow from the patient and is intended to separate a mixture of blood and bone marro... Read More
Gender:
ALL
Ages:
Between 45 years and 75 years
Trial Updated:
01/24/2022
Locations: University of California San Diego Koman Outpatient Pavilion, La Jolla, California
Conditions: Osteo Arthritis Knee
Qualification for Cone-Optogenetics
Recruiting
This study aims to prepare for the first-in-human clinical trial of cone optogenetics vision restoration. As a first step, this worldwide multicenter ocular imaging study (EyeConic Study) is performed to identify eligible patients.
Gender:
All
Ages:
All
Trial Updated:
01/19/2022
Locations: University of California San Francisco, Department of Ophthalmology, San Francisco, California
Conditions: Retinal Dystrophies